TransMedics Group (NASDAQ:TMDX) Stock Moved Up to Hold by Wall Street Zen

Wall Street Zen upgraded shares of TransMedics Group (NASDAQ:TMDX) from a sell rating to a hold rating in a research report report published on Saturday morning,Wall Street Zen reports.

Several other analysts also recently issued reports on TMDX. Needham & Company LLC boosted their target price on shares of TransMedics Group from $106.00 to $110.00 and gave the company a “buy” rating in a research note on Friday. Weiss Ratings upgraded TransMedics Group from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, August 31st. Canaccord Genuity Group raised their target price on TransMedics Group from $95.00 to $120.00 and gave the stock a “buy” rating in a research report on Friday. TD Cowen reiterated a “buy” rating and set a $120.00 price target on shares of TransMedics Group in a report on Tuesday, September 8th. Finally, Piper Sandler reissued an “overweight” rating and set a $100.00 price target (down from $120.00) on shares of TransMedics Group in a research report on Wednesday, August 5th. Five research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $118.60.

TransMedics Group Stock Performance

TransMedics Group stock opened at $88.24 on Friday. TransMedics Group has a fifty-two week low of $60.10 and a fifty-two week high of $156.00. The firm’s 50 day simple moving average is $79.61 and its 200-day simple moving average is $93.17. The company has a debt-to-equity ratio of 1.62, a current ratio of 6.62 and a quick ratio of 6.07. The company has a market cap of $3.05 billion, a P/E ratio of 23.91, a price-to-earnings-growth ratio of 1.21 and a beta of 2.14.

TransMedics Group (NASDAQ:TMDX) last issued its quarterly earnings results on Thursday, November 5th. The company reported $0.51 EPS for the quarter, beating the consensus estimate of $0.30 by $0.21. TransMedics Group had a net margin of 19.85% and a return on equity of 13.67%. The business had revenue of $203.01 million during the quarter, compared to the consensus estimate of $178.06 million. During the same quarter in the prior year, the firm earned $0.66 EPS. The firm’s quarterly revenue was up 41.1% on a year-over-year basis. As a group, equities research analysts predict that TransMedics Group will post 1.50 EPS for the current year.

Insiders Place Their Bets

In other TransMedics Group news, Director David Weill bought 1,336 shares of TransMedics Group stock in a transaction on Friday, September 11th. The stock was purchased at an average cost of $81.63 per share, for a total transaction of $109,057.68. Following the completion of the purchase, the director directly owned 16,392 shares of the company’s stock, valued at $1,338,078.96. The trade was a 8.87% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 6.90% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Pinnacle Wealth Planning Services Inc. raised its position in TransMedics Group by 24.9% in the 3rd quarter. Pinnacle Wealth Planning Services Inc. now owns 874 shares of the company’s stock worth $73,000 after purchasing an additional 174 shares during the last quarter. Plan A Wealth LLC boosted its position in TransMedics Group by 3.9% in the 3rd quarter. Plan A Wealth LLC now owns 5,370 shares of the company’s stock valued at $448,000 after buying an additional 203 shares during the last quarter. IFP Advisors Inc boosted its position in TransMedics Group by 4.8% in the 2nd quarter. IFP Advisors Inc now owns 4,652 shares of the company’s stock valued at $309,000 after buying an additional 213 shares during the last quarter. HB Wealth Management LLC boosted its position in TransMedics Group by 1.5% in the 2nd quarter. HB Wealth Management LLC now owns 15,062 shares of the company’s stock valued at $1,000,000 after buying an additional 219 shares during the last quarter. Finally, D.A. Davidson & CO. increased its stake in shares of TransMedics Group by 1.4% in the 3rd quarter. D.A. Davidson & CO. now owns 16,060 shares of the company’s stock valued at $1,340,000 after buying an additional 228 shares during the period. Institutional investors own 99.67% of the company’s stock.

Key TransMedics Group News

Here are the key news stories impacting TransMedics Group this week:

• Positive Sentiment: Third-quarter revenue was $203.0 million, up 41.1% year over year and above the roughly $178 million consensus. Adjusted earnings of $0.51 per share also beat estimates of about $0.30, supporting the growth outlook. TransMedics Q3 2026 results
• Positive Sentiment: TransMedics raised its 2026 revenue guidance to $764 million–$774 million, a signal of confidence in continued business growth. Needham also raised its price target from $106 to $110 and reiterated a Buy rating. Revenue guidance and catalyst update Needham recommendations
• Neutral Sentiment: Unusual options activity followed the earnings report, indicating heightened trading interest but not a clear directional signal. Unusual options activity report
• Negative Sentiment: ENHANCE Part B and DENOVO catalysts have shifted to early 2027, delaying potential near-term developments. EPS was also below the year-ago quarter’s $0.66, despite beating analyst estimates. Catalyst timing update

TransMedics Group Company Profile

TransMedics Group, Inc is a medical technology company focused on improving organ transplantation through systems that preserve and assess donor organs outside the body. The company’s primary platform is the Organ Care System (OCS), a portable, technology-enabled perfusion system designed to maintain organs in a functioning, near-physiologic state during transport and evaluation.

TransMedics offers OCS products for heart, lung and liver transplantation. Its systems are intended to support the use of organs that may not otherwise be suitable for conventional cold-storage methods, potentially expanding the donor pool and providing transplant teams with additional information when evaluating organs for transplantation.

Founded in 1998 and headquartered in Andover, Massachusetts, TransMedics serves transplant centers in the United States and select international markets.